PTK2 and mesothelioma: We have shown previously that the FAK inhibitor VS-4718 can abrogate the enrichment of mesothelioma CSCs resulting from exposure to the chemotherapeutic agent pemetrexed [29], but other forms of chemotherapy might differ with regard to CSC resistance.